bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

Wedbush Stays Sidelined on bluebird bio (BLUE) But Does Sees 'some short-term benefits' for the Company Following Skysona News

September 19, 2022 9:28 AM EDT

Wedbush analyst David Nierengarten reiterated a Neutral rating and $9.00 price target on bluebird bio (NASDAQ: BLUE).

The analyst comments "While we believe that the approval of SKYSONA is a win for patients suffering from CALD, we see short-term benefits for BLUE. With... More